Unique Biological Insight
Corus™ CAD is the first and only clinically validated gene expression test to deliver biological insight about obstructive* coronary artery disease (CAD). CAD develops due to a complex set of genetic, inflammatory, and environmental factors.1-4 By analyzing key sets of genes that are expressed in circulating blood cells, Corus CAD detects a reliable molecular signature that identifies patients who are likely to have obstructive CAD.5,6
- Based on a clinically validated algorithm comprised of expression levels of 23 genes demonstrated to indicate obstructive CAD
- Multi-factorial assessment of obstructive CAD based on the activity of cells and genes involved in the development of and/or response to atherosclerosis, rather than on anatomical or functional cardiac abnormalities
More Corus CAD Benefits.
* Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA).
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-1695.
- Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481-3488.
- King JY, Ferrara R, Tabibiazar R, et al. Pathway analysis of coronary atherosclerosis. Physiol Genomics. 2005;23(1):103-118. Epub 2005 Jun 7.
- Seo D, Wang T, Dressman H, et al. Gene expression phenotypes of atherosclerosis. 1: Arterioscler Thromb Vasc Biol. 2004;24(10):1922-1927. Epub 2004 Aug 5.
- PREDICT trial. Clinical trial summary found at: www.clinicaltrials.gov, NCT00500617.
- Wingrove JA, Daniels SE, Sehnert AJ, et al. Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. Circ Cardiovasc Genet. 2008; 1:31-38.
